Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings.Immunovant (IMVT +1.39%) spun out of Roivant Sciences Ltd., which reported an open-market purchase of 16,666,666 shares in the biotech company on Dec. 12, 2025, for a total value of ~$350.0 million according to the SEC Form 4 filing.Transaction summaryMetricValueShares traded16,666,666Transaction value$350.0 millionPost-transaction shares (direct)113,317,007Post-transactio ...